Europe
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Under terms of the deal, Novo Nordisk paid $725 million upfront to Sofinnova for the Waltham, Mass.-based Corvidia, a company focused on the development of transformational therapies for cardio-renal diseases.
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, announces that Helsinn is supporting Conquer Cancer, the ASCO Foundation’s COVID Impacts Cancer fund, with a donation of US$100,000.
With this capital investment, the site will be able to double its current drug substance manufacturing capacity and enhance its existing assembly operations. Production lines for bulk drug substance will be expanded, and development will begin on a new fill/finish production line.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer’s Drug
Denali Therapeutics and its development partner Sanofi announced data from its Phase Ib trial of DNL747 in Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).
The collaboration will focus on the development of three of Genmab’s bispecific antibodies and will also involve a discovery research collaboration for future antibody therapeutics for cancer.
Lundbeck stated that it is optimizing its research and development organization to strengthen and advance its pipeline.
Michael Yu, chairman and chief executive officer of Innovent Biologics, said the deal with Roche will help the company continue to move forward in the cellular therapy space.
Researchers with The U.S. Oncology Network discovered AstraZeneca’s Calquence (acalabrutinib) benefited a small number of patients who have severe infections of the novel coronavirus.
PRESS RELEASES